29 mei 2019: 

Komende maand is er weer ASCO 2019. Hier een aantal aanbevolen abstracten over studies bij mond- en keelkanker door artsen die werken voor ASCO zelf. Klik op de nummers van de abstracten

Published in Oncology

Expert Opinion / Conference Coverage · May 28, 2019

ASCO 2019: Abstract Recommendations From Dr. Barbara Burtness for Head and Neck Cancer

Session: Head and Neck Cancer
Friday May 31, 2019; 2:45 PM–5:45 PM

6000 Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). D Rischin, KJ Harrington, R Greil, et al

6006 A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy versus trans-oral robotic surgery (ORATOR). AC Nichols, J Theurer, E Prisman, et al

Session: Head and Neck Cancer
Saturday June 1, 2019; 1:15 PM–4:15 PM

6012 EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). LF Licitra, RI Haddad, C Even, et al

6013 Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS). D Adkins, J-C Lin, AG Sacco, et al

6025 CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). JE Bauman, NF Saba, TM Wise-Draper, et al

6027 Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial. F Keil, M Hartl, G Altorjai, et al

6077 Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck. S Friesland, C Mercke, H Sjödin, et al


Plaats een reactie ...

Reageer op "Aanbevolen abstracten voor mond- en keelkanker van ASCO 2019"


Gerelateerde artikelen
 

Gerelateerde artikelen

ASCO 2021: aanbevolen abstracten >> Aanbevolen abstracten voor >> ASCO 2022: aanbevolen abstracten >>